RxDoctor Payments Data

Mallory Kirkland, DPM

Foot & Ankle Surgery · Madison, ALNPI 1609337518

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,569 of the $5,253 with a category attached, or 67.9%. Stryker accounts for 75.1% of it on its own, with 14 other manufacturers making up the rest.

$5,253in general payments, 2019–2025

Across 92 payments — averaging $57.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$4K
  • Paratek Pharmaceuticals, Inc.$372
  • Kerecis Limited$289
  • Averitas Pharma Inc.$252
  • Organogenesis Inc.$61
  • Globus Medical$57
  • plus $279 from 9 others

What the payments were for

  • Travel & lodging$1,68432%
  • Food & beverage$3,56968%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,253 in reported general payments places this provider in the 60th percentile of 40 foot & ankle surgery providers in Alabama.

See all foot & ankle surgery providers in Alabama

Medicare billing

Part B allowed, 2024
$111,447
Medicare patients
326
Services billed
9,166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole12$12,834
Ciclopirox122$3,932
Ketoconazole67$1,987
Mupirocin88$726
Cephalexin82$622
Clindamycin Hcl25$364
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip15$336
Terbinafine Hcl23$305
Clotrimazole18$297
Ammonium Lactate11$279
Doxycycline Hyclate15$177
Meloxicam35$103
Fluconazole12$80
Gabapentin11$44
Triamcinolone Acetonide11$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$50$12,83412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 40 foot & ankle surgery providers in Alabama.

Other foot & ankle surgery in Madison

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →